BG96324A - PHARMACOLOGY ACTIVE SUBSTANCE VRS, METHOD OF ITS OBTAINMENT AND ITS THERAPEUTIC APPLICATION - Google Patents

PHARMACOLOGY ACTIVE SUBSTANCE VRS, METHOD OF ITS OBTAINMENT AND ITS THERAPEUTIC APPLICATION

Info

Publication number
BG96324A
BG96324A BG096324A BG9632492A BG96324A BG 96324 A BG96324 A BG 96324A BG 096324 A BG096324 A BG 096324A BG 9632492 A BG9632492 A BG 9632492A BG 96324 A BG96324 A BG 96324A
Authority
BG
Bulgaria
Prior art keywords
vrs
obtainment
active substance
therapeutic application
lyophilized
Prior art date
Application number
BG096324A
Other languages
Bulgarian (bg)
Other versions
BG61191B1 (en
Inventor
Predrag Sikiric
Marijan Petek
Ivo Rotkvic
Stjepan Mise
Simun Krizanac
Ivan Udovicic
Ernest Suchanek
Marko Duvnjak
Jerka Jukic
Original Assignee
Ernest Suchanek
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP90119376A external-priority patent/EP0432400B1/en
Application filed by Ernest Suchanek filed Critical Ernest Suchanek
Publication of BG96324A publication Critical patent/BG96324A/en
Publication of BG61191B1 publication Critical patent/BG61191B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)

Abstract

1. Метод за получаване на телесно защитно вещество врс от човешки или животински стомашен сок, характеризиращ се със следните етапи на производство: събраният и хомогенизиран животински или човешки стомашен сок се разделя на твърди части и течна супернатанта чрез центрофугиране; течната супернатанта се диализира и лиофилизира; сухият остатък се пречиства през хроматографска колона, напълнена със слабо алкална, модифицирана йонообменна смола или гел; концентратът отново се диализира и лиофилизира; сухият остатък се пречиства чрез гел-хроматография; веществото врс се получава накрая от концентрата при използване на диализа и лиофилизация. 6 претенции1. Method for obtaining body protective substance vrs from human or animal gastric juice, characterized by the following production stages: the collected and homogenized animal or human gastric juice is separated into solid parts and liquid supernatant by centrifugation; the liquid supernatant was dialyzed and lyophilized; the dry residue is purified through a chromatographic column packed with a weakly alkaline, modified ion-exchange resin or gel; the concentrate is again dialyzed and lyophilized; the dry residue is purified by gel chromatography; the vrs substance is finally obtained from the concentrate using dialysis and lyophilization. 6 claims

BG96324A 1990-09-11 1992-05-11 Pharmacologically active substance bpc, the process for its preparation and its use in the therapy BG61191B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP90119376A EP0432400B1 (en) 1989-09-12 1990-09-11 Pharmacologically active substance BPC, the process for its preparation and its use in the therapy
EP9001533 1990-09-11
PCT/EP1990/001896 WO1992004368A1 (en) 1990-09-11 1990-11-13 Pharmacologically active substance bpc, the process for its preparation and its use in the therapy

Publications (2)

Publication Number Publication Date
BG96324A true BG96324A (en) 1993-12-24
BG61191B1 BG61191B1 (en) 1997-02-28

Family

ID=26069797

Family Applications (1)

Application Number Title Priority Date Filing Date
BG96324A BG61191B1 (en) 1990-09-11 1992-05-11 Pharmacologically active substance bpc, the process for its preparation and its use in the therapy

Country Status (6)

Country Link
JP (1) JP2591875B2 (en)
AU (1) AU6901191A (en)
BG (1) BG61191B1 (en)
HU (1) HU217541B (en)
RU (1) RU2104704C1 (en)
WO (1) WO1992004368A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA61955C2 (en) * 1997-05-23 2003-12-15 Novel salts of bpc-peptides with organoprojective activity, a process for preparing and use thereof in therapy
KR20030067435A (en) * 2002-02-06 2003-08-14 유지고하라 Energy Converting Polar Plate and Method of Manufacturing
KR20030076007A (en) * 2002-03-22 2003-09-26 유지고하라 Change device of heat energy
US10350293B2 (en) * 2016-08-23 2019-07-16 Pharmacotherapia d.o.o. Compositions and methods for treating symptoms associated with multiple sclerosis
CN114632092B (en) * 2022-05-17 2022-08-23 北京第一生物化学药业有限公司 Application of testis tablet in preparing medicine with hypoglycemic activity

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1279820A (en) * 1968-12-26 1972-06-28 Nissui Pharm Co Ltd Process for preparing mucoprotein and product obtained thereby

Also Published As

Publication number Publication date
RU2104704C1 (en) 1998-02-20
HUT61320A (en) 1992-12-28
AU6901191A (en) 1992-03-30
WO1992004368A1 (en) 1992-03-19
HU9201941D0 (en) 1992-09-28
BG61191B1 (en) 1997-02-28
JPH05503089A (en) 1993-05-27
JP2591875B2 (en) 1997-03-19
HU217541B (en) 2000-02-28

Similar Documents

Publication Publication Date Title
GR3001369T3 (en) Process for eliminating cholesterol from a fatty material of animal origin, and cholesterol-impoverished fatty material obtained
DK77090A (en) Immunomodulatory AZASPIRANS
BG44538A3 (en) Method for preparing salts of 5- metoxy- 2- big bracket [(4- metoxy- 3, 5- dimethyl- 2- pyridinyl)- methyl] sulphonyl- 1h- benzimidazol
PT76502A (en) Process for the preparation of n-glycosylated carboxamide derivatives with s stimulating effect of the body's inherent defences and their application for the preparation of pharmaceutical compositions having a stimulating effect of body's inherent defences
DE69333802D1 (en) OUTER MEMBRANE PROTEIN FROM HAEMOPHILUS
RU92016463A (en) APPLICATION OF DERIVATIVES OF TISSTINES FOR THE MANUFACTURE OF MEDICINES WITH IMMUNOMODING EFFECT, PHARMACEUTICAL COMPOSITIONS ON THEIR BASIS
GR3005768T3 (en)
IL72985A0 (en) Homogenous immune interferon fragment,its manufacture and pharmaceutical compositions containing it
DE68929388D1 (en) Anticoagulant compound isolated from urine
GB8824869D0 (en) Synthetic antibody
BG96324A (en) PHARMACOLOGY ACTIVE SUBSTANCE VRS, METHOD OF ITS OBTAINMENT AND ITS THERAPEUTIC APPLICATION
BE900012A (en) NEW PEPTIDE.
Guerranti et al. Characterization of the factor responsible for the antisnake activity of Mucuna pruriens seeds
YU176089A (en) PROCEDURE FOR PREPARATION OF BPC SUBSTANCE AND BPC SUBSTANCE
ATE130192T1 (en) USE OF 15-DEOXYSPERGUALIN AS A MEDICINAL PRODUCT.
GB2003887A (en) Isolation of peptides from urine
KR920017663A (en) Refined tick allergens
AU2459188A (en) Anticoagulative protein pp4-x, and its preparation and use
JPS6468326A (en) Remedy for athlete's foot
KR970058708A (en) Medical use of l-muscone
BG50942A3 (en) Method for production of chymopapain
Baum et al. Isolation and characterization of a galactose-specific carbohydrate binding protein from human lymphoblastic cells
SU1732518A1 (en) Method of immunoglobulin m preparing
ES2158776A1 (en) Application of gamma globulin-rich plasma proteins of animal origin for the preparation of medicinal compositions, food and dietary preparations to prevent and treat specific disorders in human beings and animals
RO102778A2 (en) Producing method of human anti-transpherine serum